






of	 the	 adult	 canine	 population.	 Other	 causes	 of	 arthritis	 include,	 for	 example,	 immune	
medicated	 and	 sepsis.	 In	 dogs	 both	 primary	 and	 secondary	 forms	 of	 osteoarthritis	 occur	
although	the	secondary	form	is	far	more	common.	This	form	occurs	following	injury	or	insult	

















osteoarthritis.	 In	 dogs,	 osteoarthritis	 has	 specific	 breed	 and	 age	 predilections	 so	 the	
signalment	 of	 an	 animal	may	 help	 the	 clinician	 in	 reaching	 a	 diagnosis.	 For	 example,	 hip	












The	most	common	manifestation	of	osteoarthritis	 is	 so-called	 ‘inactivity	stiffness’.	Owners	
report	 that	 their	 pet’s	 lameness	 seems	 to	 resolve	 during	 exercise	 but	 then	worsens	 after	















examination	 should	be	 systematic	and	complete.	 It	 is	useful	 to	 compare	 the	 contralateral	
limb	when	assessing	the	range	of	motion,	and	also	when	looking	for	soft	tissue	swelling	and	
muscle	 atrophy.	 However,	 since	 the	 most	 common	 forms	 of	 orthopaedic	 disease	 (eg,	
cruciate	disease,	elbow	dysplasia	and	hip	dysplasia)	can	frequently	present	bilaterally	this	is	
not	always	useful.	
	A	complete	analysis	of	 the	gait	 should	be	performed.	This	 is	most	commonly	done	 in	 two	
ways:	
• The	 patient	 can	 be	 examined	 while	 in	 the	 consultation	 room	 during	 the	
history	 taking.	 This	 can	 often	 reveal	 very	 subtle	 lameness	 and	 allows	 the	
clinician	 to	 monitor	 the	 animal	 lying	 down	 and	 standing	 up	 as	 well	 when	
walking	around	the	consultation	room.	
• Further	analysis	of	the	gait	should	be	made	in	an	area	that	allows	the	animal	
to	be	walked	and	 trotted	 in	 a	 straight	 line.	 The	animal	 should	be	observed	
walking	away	from	and	back	towards	the	clinician,	as	pelvic	limb	lameness	is	
often	more	 obvious	 when	 walking	 away	 and	 thoracic	 limb	 lameness	 when	
walking	back	towards	the	clinician.			
• This	 is	 usually	 performed	 before	 the	 physical	 examination	 as	 the	 lameness	





















test	 for	 cruciate	 ligament	 disease.	 It	 is	 often	 better	 to	 perform	 these	 latter	 tests	 under	
sedation	as	they	can	be	painful	for	the	patient	and	difficult	to	interpret	in	conscious	animals	
	









Radiography	 is	 the	 mainstay	 in	 clinical	 practice	 for	 diagnosis	 of	 osteoarthritis	 in	 dogs.	
However,	 its	 limitations	 must	 be	 appreciated	 as	 it	 mainly	 provides	 information	 on	 the	
osseous	changes,	such	as	sclerosis	and	osteophyte	formation,	providing	a	limited	amount	of	










Although	 the	 presence	 of	 osteophytes	 can	 be	 used	 to	 diagnose	 osteoarthritis,	 there	 is	 a	
tendency	for	clinicians	is	to	focus	on	these	osseous	changes	even	if	they	do	not	necessarily	
correlate	 well	 to	 severity	 of	 disease	 or	 the	 clinical	 situation	 seen.	 Elbow	 dysplasia,	 for	
example,	produces	osteophytes	very	slowly	whereas	within	three	or	four	weeks	of	a	cranial	
cruciate	 ligament	 rupture	 there	will	be	 radiographic	evidence	of	osteoarthritis.	 It	has	also	





Subchondral	 sclerosis	 is	 commonly	 quoted	 as	 an	 indicator	 of	 osteoarthritis	 although	 its	
sensitivity	on	plain	radiography	is	limited,	due	to	the	wide	variation	in	exposure	factors	that	
can	 lead	 to	 apparent	 differences	 in	 density,	 and,	 in	 one	 study,	 detection	 of	 subchondral	
sclerosis	was	unacceptably	low	among	board-certified	radiologists	(Innes	and	others	2004).	
Care	 should	 be	 taken	 to	 not	 overinterpret	 this	 radiographic	 finding	 because,	 taken	 in	





of	 fluid	may	 be	 increased,	 cell	 counts	 (predominantly	monocytes	 (>88%)	 are	 usually	 low	
(less	 than	 5x	 109	WBC/l)	 and	 can	 often	 be	within	 normal	 limits	 (<2	 x109	WBC/l),	 and	 the	
colour	 remains	 clear	 to	 pale	 yellow.	 In	 the	 early	 stages	 of	 the	 disease	 viscosity	 is	 not	
reduced	although,	as	the	hyaluronic	acid	concentration	diminishes	over	time,	the	viscosity	








clinicians	 and,	 therefore,	 their	 use	 is	 increasing	 in	 the	work-up	 of	 orthopaedic	 cases.	 For	
patients	with	osteoarthritis,	CT	can	be	useful	in	the	early	stages	of	disease,	as	it	may	help	to	
identify	 the	 primary	 lesion	 which	may	 not	 be	 present	 or	 obvious	 on	 radiographs.	 This	 is	
particularly	 the	 case	 for	 elbow	 dysplasia,	 where	 the	 primary	 medial	 coronoid	 disease	 is	










Scintigraphy	 is	 very	 limited	 in	 its	 availability	 due	 to	 the	 restrictions	 governing	 the	 use	 of	
radioactive	 material.	 Its	 relative	 lack	 of	 usefulness	 clinically	 also	 limits	 its	 use.	 As	 it	 can	
readily	 identify	 areas	 of	 increased	 bone	 turnover,	 it	 is	 most	 commonly	 used	 in	 cases	 of	
occult	lameness	where	the	source	of	the	lameness	is	not	obvious.		
	
Arthroscopy	 Although	 mainly	 considered	 to	 be	 a	 surgical	 tool,	 arthroscopy	 also	 has	 a	
diagnostic	 application	 and,	 given	 its	 ever-increasing	 availability,	 now	 offers	 the	 best	 and	
most	 cost-effective	 method	 for	 staging	 osteoarthritis	 in	 dogs	 (see	 surgical	 management	
section	below).		Depending	upon	the	joint	involved	arthroscopic	surgery	may	involve:	
	















Although	 one	 study	 demonstrated	 that	 a	 short	 period	 of	 exercise	 (1.2	 km	 of	 trotting)	
increased	the	degree	of	lameness	when	measured	on	a	force	platform	(Beraud	and	others	
2010),	very	little	is	really	known	about	the	effects	of	exercise	on	osteoarthritis.	In	people	it	
does	 seem	 that	 some	exercise	may	be	beneficial	 and	 certainly	 in	 canine	patients	exercise	
should	 be	 moderated	 but	 continued.	 Anecdotally,	 no	 exercise	 may	 be	 as	 detrimental	 as	
doing	 extremes	 of	 exercise.	 When	 advising	 owners	 on	 exercise	 levels	 for	 their	 dog	 it	 is	
important	to	advise	them	to	try	and	avoid	exuberant	activities	such	as	chasing	balls,	agility	
activities	 or	 other	 forms	 of	 high-energy	 exercise.	 When	 a	 flare-up	 of	 osteoarthritis	 has	
occurred	 for	most	patients	 the	best	course	of	action	 is	 to	 reduce	 the	 levels	of	exercise	 to	

















It	 is	 important	 for	clinicians’	 to	abide	by	the	Cascade	system	when	prescribing	medication	
for	 the	management	 of	 osteoarthritis	 and	 not	 just	 go	 for	 the	more	 ‘fashionable’	 options.	
Most	 cases	 of	 osteoarthritis,	 especially	 in	 the	 early	 stages,	 can	more	 than	 adequately	 be	





an	ever	 increasing	range	of	 licensed	products	 is	available	 for	dogs	(Fig	1).	NSAIDs	work	by	
inhibiting	 the	 cyclooxygenase	 (COX)	 enzyme	 in	 order	 to	 reduce	 prostaglandin	 production.	
Two	main	forms	of	COX	exist,	namely	COX	1	(constitutive)	and	COX	2	(inducible),	although	








to	 allow	 analgesia	 to	 occur	 without	 creating	 the	 common	 side	 effects	 (in	 particular	
gastrointestinal	 irritation	 and	 ulceration,	 nausea,	 diarrhoea	 and	 renal	 papillary	
necrosis)associated	with	inhibiting	COX	1.	A	drug	that	selectively	induces	COX	2	inhibition	at	
a	concentration	lower	than	that	needed	to	inhibit	COX	1	is	potentially	safer	although	this	is	
an	 oversimplification	 of	 the	 actual	 situation.	 There	 is	 not	 a	 clear	 distinction	 between	 the	
pathways	of	constitutive	and	inducible	prostaglandins	and,	in	some	cases,	Cox	2	provides	a	
protective	effect	(e.g.	in	inflamed	gastrointestinal	mucosa)	.	However	drugs	(e.g	meloxicam	







allows	 the	 clinician	 to	 prescribe	 long-term	 therapies	 although	 it	 is	 prudent	 to	 reduce	 the	
levels	to	the	lowest	effective	dose	(which	may	be	below	that	stated	in	the	data	sheets),	with	












osteoarthritis,	 within	 the	 license,	 is	 therefore	 limited.	 However,	 in	 the	 human	 field	
paracetamol	 is	 now	 routinely	 used	 in	 conjunction	with	NSAIDs	 as	 an	 alternating	 protocol	
and	we	use	similar	protocols	in	our	practice,	albeit	off	license.	The	licensed	dose	for	Pardale	



















Gabapentin	 and	 amantadine	 are	 drugs	 that	 are	 designed	 to	manage	 chronic	 pain	 but	 are	
unlicensed.	Amantadine	works	by	acting	on	the	N-methyl-D-aspartate	(NMDA)	receptor	and	
reduces	 the	 prolonged	 inflammatory	 pain	 associated	 with	 chronic	 disease.	 One	 study	 of	
dogs	 showed	an	 improvement	 in	 terms	of	both	 veterinary-	 and	owner-assessed	 lameness	
when	 used	 with	 meloxicam	 compared	 to	 those	 case	 on	 meloxicam	 only;	 by	 day	 42,	 the	
amantadine	and	meloxicam	group	had	improved	scores	(Lascelles	and	others	2008)	.	
	
Gabapentin	 works	 on	 the	 g-aminobutyric	 acid	 (GABA)	 receptor	 and	 is	 thought	 to	 reduce	
neuropathic	pain,	although	its	exact	mechanism	is	not	known.	The	use	of	these	drugs	should	
not	be	routine	and	each	case	where	this	is	being	considered	needs	to	be	carefully	judged.	




The	 use	 of	 these	 drugs	 in	 the	 management	 of	 osteoarthritis	 is	 generally	 restricted	 to	









Structure-modifying	drugs	are	 less	 available	 for	 dogs	 due	 to	 the	 strict	 criteria	 needed	 to	
validate	 such	 drugs.	 The	 main	 example	 includes	 pentosan	 polysulphate	 (Cartrophen;	
Biopharm	Australia),	which	is	a	licensed	product	made	from	beech	and	similar	in	structure	





A	 lot	 of	 effort	 has	 gone	 into	 the	 development	 of	 nutritional	 means	 of	 managing	
osteoarthritis	 recently	 and	 an	 ever-increasing	 number	 of	 nutraceutical	 products	 are	
available	to	the	clinician.	However,	the	majority	of	these	show	only	anecdotal	evidence	of	
efficacy	with	little	evidence	to	support	their	claims.	As	opposed	to	pharmaceutical	products,	
which	 are	 under	 the	 direct	 regulation	 of	 the	 Veterinary	 Medicines	 Directorate	 (VMD)	
through	the	Veterinary	Medicines	Regulations	2006,	nutraceuticals	are	not	subjected	to	the	
same	restrictions	unless	they	make	specific	health	claims.	The	definition	of	what	constitutes	
a	 health	 claim	 is	 quite	 vague	 but	 essentially	 any	 claim	 relating	 to	 a	 specific	 disease,	 as	





is	 the	 rationale	 for	 its	 use	 in	 osteoarthritis.	 However,	 the	 efficacy	 of	 glucosamine	 in	 vivo	




osteoarthritis	 are	 debatable	 and	 two	 large	 double-blinded	 negative-controlled	 studies	




Essential	 fatty	 acids,	 in	 particular	 omega	 3,	 have	 been	 shown	 to	 affect	 synovial	 fluid	
metalloproteinase	 and	 tissue	 inhibitors	 of	 metalloproteinase	 concentrations	 following	
surgery	 for	 rupture	 of	 the	 cranial	 cruciate	 ligament	 (Hansen	 and	 others	 2008)	 .	 Further	
studies	 using	 objective	 outcome	 measures	 showed	 significantly	 increased	 levels	 of	 peak	











and	more	 likely	 to	 show	 signs	 of	 chronic	 pain	 than	dogs	with	 an	 ideal	weight.	 Therefore,	
weight	 control	 can	 be	 a	 useful	 adjunct	 therapy	 for	 overweight	 dogs	 with	 concurrent	
osteoarthritis.	 Indeed,	 recent	 studies	 (Mlacknik	 et	 al	 2006;	 Marshall	 et	 al	 2010)	 have	
demonstrated	 that	 weight	 loss	 can	 significantly	 improve	 the	 gait	 of	 obese	 osteoarthritic	
dogs,	 as	 judged	 by	 force-plate	 analysis.	 There	 is	 also	 evidence	 of	 improved	 quality	 of	 life	
when	 obese	 dogs	 lose	 weight,	 and	 this	 includes	 significant	 improvements	 in	 activity	 and	
evidence	 of	 a	 decrease	 in	 chronic	 pain.	 So,	 while	 the	 evidence	 for	 many	 therapeutic	
measures	(including	nutritional	modification)	have	not	been	well	established,	the	benefits	of	
weight	loss	are	clear.	It	is	worth	emphasising	that	the	benefits	of	increased	mobility	can	be	
demonstrated	 with	 only	 a	 modest	 amount	 of	 weight	 loss;	 improvements	 in	 gait	 can	 be	
observed	on	force-plate	analysis	once	body	weight	 loss	exceeds	6	per	cent	 (Marshall	et	al	






Janssen)	 for	 controlled	 weight	 loss	 in	 overweight	 dogs.	 While	 the	 reported	 efficacy	 in	
published	studies	was	good	(Gossellin	et	al	2007;	Pena	et	al	2014),	performance	in	clinical	
practice	was	more	disappointing,	and	they	failed	to	gain	widespread	acceptance.	In	light	of	
this,	 both	 drugs	 have	 been	 withdrawn	 from	 the	 market.	 Therefore,	 the	 most	 widely	




medical	management	 and	 surgery.	 The	 sooner	 a	weight	management	 protocol	 is	 started,	
the	sooner	 the	benefits	will	be	observed.	That	said,	because	 the	process	can	 take	 time,	 it	
should	 not	 be	 used	 as	 the	 sole	 strategy,	 as	 other	medical	 therapies	 can	 alleviate	 clinical	
signs	 sooner.	 Indeed,	 combining	 weight	 management	 with	 other	 strategies	 might	
improvement	 outcomes;	 for	 example,	 if	 analgesia	 alleviates	 chronic	 pain,	mobility	 can	 be	
improved	and	this	might	help	to	promote	weight	loss.	The	timing	of	weight	management	in	
relation	to	surgery	should	also	be	considered.	Successful	surgery	can	improve	mobility	and	
again	may	 improve	 the	 outcomes	 of	 weight	 loss;	 however,	 delaying	 surgery	 until	 after	 a	
period	of	weight	loss	may	reduce	the	risks	of	complications	of	the	procedure.	It	might	also	
be	 that,	 as	 mobility	 improves,	 the	 need	 for	 surgery	 deceases.	 As	 a	 general	 guide	 for	 an	
overweight	dog	with	concurrent	osteoarthritis,	we	would	suggest	a	short	period	of	weight	
management	(two	to	three	months)	before	any	surgical	procedure,	provided	that	this	delay	






used	 because	 they	 tend	 to	 be	 supplemented	 in	 essential	 nutrients	 relative	 to	 energy	
content,	 which	 reduces	 the	 chance	 of	 malnutrition	 arising.	 These	 diets	 are	 often	
supplemented	with	protein	and	fibre,	which	is	known	to	minimise	signs	of	hunger	in	the	pet	
thereby	improving	owner	compliance.	Food	intake	during	weight	loss	should	be	accurately	
measured,	with	 the	 exact	 amount	 fed	 depending	 upon	 the	 food	 used,	 the	 dog’s	 sex	 and	




use	 of	 measuring	 cups)	 are	 unreliable	 and	 usually	 lead	 to	 overfeeding.	 Table	 scraps	 and	
treats	 should	be	 avoided,	 although	 some	 treats	 (especially	 those	with	 a	purported	health	
benefit	 such	as	a	dental	 chew)	can	be	allowed,	provided	 that	 the	energy	content	 is	 taken	
into	 account	within	 the	 feeding	 strategy.	A	 final	 consideration	 is	 how	 the	 food	 should	be	
fed.	Rather	than	using	feeding	bowls,	puzzle	feeders	are	a	good	idea,	and	these	can	either	
be	hollow	toys	or	modified	 feed	bowls.	The	devices	have	been	shown	to	slow	feed	 intake	





programme.	 Owners	 often	 struggle	 with	 weight	 management	 programme	 for	 their	 pet	
because	of	the	strength	of	the	owner-pet	bond,	and	the	fact	that	they	are	deprived	of	the	
main	method	 they	use	 to	demonstrate	 love	 to	 their	 pet.	 Strategies	 that	 increase	physical	
activity	can	provide	an	alternative	means	 for	an	owner	to	 interact	with	their	pet.	There	 is	
also	emerging	evidence	that	including	such	strategies	into	weight	management	programmes	
might	 improve	the	outcomes	(Chauvet	et	al	2011).	Suitable	strategies	 include	regular	 lead	

















and	 other	 conservative	 measures.	 However,	 for	 some	 patients	 and	 some	 joints,	 the	
response	 is	 poor	 and	 surgical	 management	 should	 be	 considered.	 Although	 arthroscopic	




Joint	 replacements	 are	 readily	 available	 for	 the	 hip,	 stifle	 and	 elbow	 although	 bespoke	
replacements	have	been	performed	 in	other	 joints.	Of	 these,	 the	 total	hip	 replacement	 is	
currently	 the	 most	 commonly	 performed	 and	 most	 reliable	 arthroplasty,	 with	 good	 to	
excellent	 function	being	achieved	 in	more	than	90	per	cent	of	cases	 (Allen	2012)	 .	Such	 is	
the	 success	of	 this	procedure	 that	 intervention	 is	now	performed	at	 a	much	earlier	 stage	
than	 previously	 recommended.	 Dogs	 in	 their	 early	 adult	 years	 with	 pain	 associated	 with	





In	 some	 cases,	 total	 joint	 replacement	 is	 not	 possible	 and	 arthrodesis	may	 be	 a	 suitable	
alternative.	This	has	the	effect	of	removing	the	intractable	pain	although	it	produces	a	rigid	
joint	and	so	is	better	suited	to	the	low	motion	joints	such	as	the	carpus	and	tarsus.	Elbow,	
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chewable tablet  
Dogs  
    
Phenylbutazone Phenylbutazone 200mg tablets Dogs 
    
Mavacoxib Trocoxil 6, 20, 30, 75 or 95mg 
chewable tablets 
Dogs  
    
Cimicoxib Cimalgex 8, 30, 80mg chewable tablets Dogs  
    
 Tolfedine 6, 20 and 60mg tablets Dogs/cats  
    
Chinchophen PLT 200mg (plus 1mg 
prednisolone) 
Dogs  
    
Robenacoxib Onsior 6mg flavoured tablets Cats 
Onsior 5, 10, 20 and 40mg flavoured 
tablets 
Dogs 
Onsior 20mg/ml solution  Dogs/cats 
    
Firocoxib Previcox 57 and 227mg chewable 
tablets 
Dogs  
    
Ketoprofen Ketofen 5, 20mg tablets Dogs 
Ketofen 1% solution  Dogs 
    
Tolfenamic acid  Tolfedine  4% injection Dogs/cats  
Tolfedine 6, 20, 60 mg tablets  Dogs/cats  
